Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer

Introduction: HER2 overexpression/amplification occurs in 15-20% breast cancers (BC) and is associated with worse prognosis. The addition of anti-HER2 treatment to neoadjuvant chemotherapy significantly improves the pathological complete response (pCR) rate. Changes in HER2 status after neoadjuvant...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Transl Res
Asıl Yazarlar: Branco, Francisco P, Machado, Duarte, Silva, Filipa F, André, Saudade, Catarino, Ana, Madureira, Rosa, Pinto, João M, Godinho, João P, Simões, Pedro D, Brito, Margarida, Casa-Nova, Mafalda, Moreira, António R, Passos-Coelho, José L
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: e-Century Publishing Corporation 2019
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6789273/
https://ncbi.nlm.nih.gov/pubmed/31632579
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller